Flux XII LLC

The Wisconsin & Southern Railroad Company is a privately owned and managed regional railroad company operating in the southern half of the State of Wisconsin and northeastern Illinois. The company operates over 600 miles of branch and mainline track traversing a total of 20 counties in Wisconsin and Illinois. The Wisconsin and Southern Railroad is Wisconsin s third largest railroad. Headquartered in Milwaukee the Wisconsin and Southern Railroad connects within the state with all the western Class One railroads Burlington Northern Santa Fe, Canadian National, Canadian Pacific and Union Pacific. With direct access to Chicago, Wisconsin and Southern connects with the eastern Class One s CSX and Norfolk Southern. In addition to the Belt Railway in Chicago, the railroad also has access to harbor facilities in Prairie du Chien. Wisconsin and Southern has branch offices in Janesville, Madison and Horicon. Since its inception in 1980, WSOR has quadrupled the freight business served on the lines by their previous owners. The company employs more than 200 people.

Occupy Madison Inc is a non-profit organization based in Madison, WI, dedicated to creating sustainable housing solutions through the development of tiny house villages. Their innovative approach aims to address homelessness by providing a supportive community environment for residents. With a focus on volunteerism and community involvement, Occupy Madison Inc empowers individuals to build their own homes and contribute to the cooperative living model. Through their efforts, they strive to make a positive impact on the lives of those in need and promote a more inclusive and compassionate society.Generated from the website

Endsulin LLC, based in Madison, WI, is a pioneering biotech company focused on developing a groundbreaking genetic therapy for Type 1 Diabetes. Founded by a world-renowned scientist and transplant surgeon, the company aims to revolutionize diabetes treatment by re-engineering liver cells to enable the body to produce and regulate its own insulin. With a mission to provide long-term relief from the burden of artificial insulin dependence, Endsulin's innovative approach seeks to offer patients a single infusion treatment without the need for immunosuppressive agents. Through years of university research and a team of leading experts in gene therapy and regulatory affairs, Endsulin is dedicated to realizing the goal of freeing diabetes patients from the constraints of traditional insulin management.Generated from the website